E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Marine Glycobiology, Glycomics and Lectins"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 31 December 2018

Special Issue Editor

Guest Editor
Prof. Yasuhiro Ozeki

Department of life and environmental system science, Graduate school of NanoBiosciences, Yokohama City University, 22-2 Seto, Kanazawa-ku, Yokohama, 236-0027, Japan
Website | E-Mail
Phone: +81-45-787-2221
Fax: +81 45 787 2413
Interests: Diversification of marine lectins; Evolutional and comparative views of glycan-related genes; lectin-mediated cell signaling; Marine glycomedicine

Special Issue Information

Dear Colleagues,

Glycans (carbohydrate chains) of marine creatures are rich and diverse in glycoproteins and glycolipids, and also glycan-related enzymes (glycosyltransferases and glycosidases). They are recognized by themselves (carbohydrate-carbohydrate interaction), and/or by lectins (glycan-binding proteins), which regulate comprehensive cellular manners such as growth, differentiation and death. These views lead us to combine the subjects for both marine life systems and human diseases. Standing on the background of glycan-based biosciences (glycobiology), this Special Issue, "Marine Glycobiology, Glycomics and Lectins", welcomes your articles and reviews. Marine glycomics that involves the glycoproteome and transcriptome accelerates our understanding of evolution of glycans, glycan-related enzymes and lectins. Glycomics also promotes the application of marine glycobiology to discover novel biomaterials which contribute to drug development. Lastly, as a useful resource, there are many kinds of lectins, which have versatile glycan-binding specificities and can decipher the codes of diverse glycan structures. They have strong potential to be applicable to medicine and diagnostics for regeneration and/or cancer therapy in the future.

Prof. Yasuhiro Ozeki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Carbohydrate-carbohydrate interaction

  • Protein-carbohydrate interaction

  • Marine lectins

  • Structural glycobiology

  • Glycoproteome

  • Transcriptome

  • Glycomicrbiology

  • Glycosphingolipids

  • Glycosaminoglycans

  • Marine glycomedicine

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Research

Open AccessArticle Tachypleus tridentatus Lectin Enhances Oncolytic Vaccinia Virus Replication to Suppress In Vivo Hepatocellular Carcinoma Growth
Mar. Drugs 2018, 16(6), 200; https://doi.org/10.3390/md16060200
Received: 20 May 2018 / Revised: 1 June 2018 / Accepted: 5 June 2018 / Published: 7 June 2018
PDF Full-text (1921 KB) | HTML Full-text | XML Full-text
Abstract
Lectins play diverse roles in physiological processes as biological recognition molecules. In this report, a gene encoding Tachypleus tridentatus Lectin (TTL) was inserted into an oncolytic vaccinia virus (oncoVV) vector to form oncoVV-TTL, which showed significant antitumor activity in a hepatocellular carcinoma mouse
[...] Read more.
Lectins play diverse roles in physiological processes as biological recognition molecules. In this report, a gene encoding Tachypleus tridentatus Lectin (TTL) was inserted into an oncolytic vaccinia virus (oncoVV) vector to form oncoVV-TTL, which showed significant antitumor activity in a hepatocellular carcinoma mouse model. Furthermore, TTL enhanced oncoVV replication through suppressing antiviral factors expression such as interferon-inducible protein 16 (IFI16), mitochondrial antiviral signaling protein (MAVS) and interferon-beta (IFN-β). Further investigations revealed that oncoVV-TTL replication was highly dependent on ERK activity. This study might provide insights into a novel way of the utilization of TTL in oncolytic viral therapies. Full article
(This article belongs to the Special Issue Marine Glycobiology, Glycomics and Lectins)
Figures

Figure 1

Open AccessArticle Haliotis discus discus Sialic Acid-Binding Lectin Reduces the Oncolytic Vaccinia Virus Induced Toxicity in a Glioblastoma Mouse Model
Mar. Drugs 2018, 16(5), 141; https://doi.org/10.3390/md16050141
Received: 4 April 2018 / Revised: 22 April 2018 / Accepted: 25 April 2018 / Published: 26 April 2018
PDF Full-text (1560 KB) | HTML Full-text | XML Full-text
Abstract
Although oncolytic viruses provide attractive vehicles for cancer treatment, their adverse effects are largely ignored. In this work, rat C6 glioblastoma cells were subcutaneously xenografted into mice, and a thymidine kinase-deficient oncolytic vaccinia virus (oncoVV) induced severe toxicity in this model. However, oncoVV-HddSBL,
[...] Read more.
Although oncolytic viruses provide attractive vehicles for cancer treatment, their adverse effects are largely ignored. In this work, rat C6 glioblastoma cells were subcutaneously xenografted into mice, and a thymidine kinase-deficient oncolytic vaccinia virus (oncoVV) induced severe toxicity in this model. However, oncoVV-HddSBL, in which a gene encoding Haliotis discus discus sialic acid-binding lectin (HddSBL) was inserted into oncoVV, significantly prolonged the survival of mice as compared to the control virus. HddSBL reduced the tumor secreted serum rat IL-2 level upregulated by oncoVV, promoted viral replication, as well as inhibited the expression of antiviral factors in C6 glioblastoma cell line. Furthermore, HddSBL downregulated the expression levels of histone H3 and H4, and upregulated histone H3R8 and H4R3 asymmetric dimethylation, confirming the effect of HddSBL on chromatin structure suggested by the transcriptome data. Our results might provide insights into the utilization of HddSBL in counteracting the adverse effects of oncolytic vaccinia virus. Full article
(This article belongs to the Special Issue Marine Glycobiology, Glycomics and Lectins)
Figures

Figure 1

Back to Top